Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells.

Fitzsimmons L, Boyce AJ, Wei W, Chang C, Croom-Carter D, Tierney RJ, Herold MJ, Bell AI, Strasser A, Kelly GL, Rowe M.

Cell Death Differ. 2018 Feb;25(2):241-254. doi: 10.1038/cdd.2017.150. Epub 2017 Sep 29.

2.

Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.

Abbott RJ, Pachnio A, Pedroza-Pacheco I, Leese AM, Begum J, Long HM, Croom-Carter D, Stacey A, Moss PAH, Hislop AD, Borrow P, Rickinson AB, Bell AI.

J Virol. 2017 Oct 13;91(21). pii: e00382-17. doi: 10.1128/JVI.00382-17. Print 2017 Nov 1.

3.

Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.

Kelly GL, Stylianou J, Rasaiyaah J, Wei W, Thomas W, Croom-Carter D, Kohler C, Spang R, Woodman C, Kellam P, Rickinson AB, Bell AI.

J Virol. 2013 Mar;87(5):2882-94. doi: 10.1128/JVI.03003-12. Epub 2012 Dec 26.

4.

Epstein-Barr virus infection of naïve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology.

Heath E, Begue-Pastor N, Chaganti S, Croom-Carter D, Shannon-Lowe C, Kube D, Feederle R, Delecluse HJ, Rickinson AB, Bell AI.

PLoS Pathog. 2012;8(5):e1002697. doi: 10.1371/journal.ppat.1002697. Epub 2012 May 10.

5.

Revisiting the effect of acute P. falciparum malaria on Epstein-Barr virus: host balance in the setting of reduced malaria endemicity.

Jayasooriya S, Hislop A, Peng Y, Croom-Carter D, Jankey Y, Bell A, Dong T, Rowland-Jones S, Rickinson A, Walther M, Whittle H.

PLoS One. 2012;7(2):e31142. doi: 10.1371/journal.pone.0031142. Epub 2012 Feb 8.

6.

Epstein-Barr virus latent gene sequences as geographical markers of viral origin: unique EBNA3 gene signatures identify Japanese viruses as distinct members of the Asian virus family.

Sawada A, Croom-Carter D, Kondo O, Yasui M, Koyama-Sato M, Inoue M, Kawa K, Rickinson AB, Tierney RJ.

J Gen Virol. 2011 May;92(Pt 5):1032-43. doi: 10.1099/vir.0.030023-0. Epub 2011 Jan 19.

PMID:
21248177
7.

The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children.

Njie R, Bell AI, Jia H, Croom-Carter D, Chaganti S, Hislop AD, Whittle H, Rickinson AB.

J Infect Dis. 2009 Jan 1;199(1):31-8. doi: 10.1086/594373.

PMID:
19032105
8.

Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients.

Chaganti S, Ma CS, Bell AI, Croom-Carter D, Hislop AD, Tangye SG, Rickinson AB.

Blood. 2008 Aug 1;112(3):672-9. doi: 10.1182/blood-2007-10-116269. Epub 2008 May 28.

9.

Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.

Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, Rickinson AB.

J Gen Virol. 2006 Oct;87(Pt 10):2885-90.

PMID:
16963746
10.

Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays.

Tierney RJ, Edwards RH, Sitki-Green D, Croom-Carter D, Roy S, Yao QY, Raab-Traub N, Rickinson AB.

J Infect Dis. 2006 Jan 15;193(2):287-97. Epub 2005 Dec 14.

PMID:
16362894
11.

Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.

Kelly GL, Milner AE, Tierney RJ, Croom-Carter DS, Altmann M, Hammerschmidt W, Bell AI, Rickinson AB.

J Virol. 2005 Aug;79(16):10709-17.

12.

HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

Midgley RS, Bell AI, Yao QY, Croom-Carter D, Hislop AD, Whitney BM, Chan AT, Johnson PJ, Rickinson AB.

J Virol. 2003 Nov;77(21):11507-16.

13.

Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2.

Lautscham G, Haigh T, Mayrhofer S, Taylor G, Croom-Carter D, Leese A, Gadola S, Cerundolo V, Rickinson A, Blake N.

J Virol. 2003 Feb;77(4):2757-61.

14.

B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.

Moosmann A, Khan N, Cobbold M, Zentz C, Delecluse HJ, Hollweck G, Hislop AD, Blake NW, Croom-Carter D, Wollenberg B, Moss PA, Zeidler R, Rickinson AB, Hammerschmidt W.

Blood. 2002 Sep 1;100(5):1755-64.

15.

Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells.

Harris RS, Croom-Carter DS, Rickinson AB, Neuberger MS.

J Virol. 2001 Nov;75(21):10488-92.

16.

The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.

Blake N, Haigh T, Shaka'a G, Croom-Carter D, Rickinson A.

J Immunol. 2000 Dec 15;165(12):7078-87.

17.

Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.

Brooks JM, Croom-Carter DS, Leese AM, Tierney RJ, Habeshaw G, Rickinson AB.

J Virol. 2000 Feb;74(4):1801-9.

18.

Novel intertypic recombinants of epstein-barr virus in the chinese population.

Midgley RS, Blake NW, Yao QY, Croom-Carter D, Cheung ST, Leung SF, Chan AT, Johnson PJ, Huang D, Rickinson AB, Lee SP.

J Virol. 2000 Feb;74(3):1544-8.

19.
20.

Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Yao QY, Croom-Carter DS, Tierney RJ, Habeshaw G, Wilde JT, Hill FG, Conlon C, Rickinson AB.

J Virol. 1998 May;72(5):4352-63.

21.

Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals.

Yao QY, Tierney RJ, Croom-Carter D, Cooper GM, Ellis CJ, Rowe M, Rickinson AB.

J Virol. 1996 Aug;70(8):4895-903.

22.

Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals.

Yao QY, Tierney RJ, Croom-Carter D, Dukers D, Cooper GM, Ellis CJ, Rowe M, Rickinson AB.

J Virol. 1996 Aug;70(8):4884-94.

23.

Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.

Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR, et al.

Eur J Immunol. 1995 May;25(5):1374-84.

PMID:
7774641
26.

Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage.

Kerr BM, Lear AL, Rowe M, Croom-Carter D, Young LS, Rookes SM, Gallimore PH, Rickinson AB.

Virology. 1992 Mar;187(1):189-201.

PMID:
1310556
27.

Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB.

J Virol. 1992 Jan;66(1):122-31.

28.

Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.

Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A.

Cell. 1991 Jun 28;65(7):1107-15.

PMID:
1648447

Supplemental Content

Loading ...
Support Center